Organon & Co. (OGN)
(Delayed Data from NYSE)
$19.05 USD
+0.40 (2.14%)
Updated Aug 7, 2024 04:00 PM ET
After-Market: $19.05 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth A Momentum A VGM
Price, Consensus and EPS Surprise
OGN 19.05 +0.40(2.14%)
Will OGN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for OGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for OGN
Organon (OGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Organon (OGN) Surpasses Q2 Earnings Estimates
OGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Product Demand Likely to Aid Organon's (OGN) Q2 Earnings
Do Options Traders Know Something About Organon (OGN) Stock We Don't?
Seeking Clues to Organon (OGN) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Other News for OGN
Analysts Have Conflicting Sentiments on These Healthcare Companies: Organon (OGN), Stevanato Group (STVN) and DaVita (DVA)
Bank of America Securities Keeps Their Sell Rating on Organon (OGN)
Morgan Stanley Remains a Hold on Organon (OGN)
Organon’s Mixed Performance and Cautious Outlook: A Hold Rating Justified
Origin Enterprises Buys Back Shares